1 / 47

Osteoporosis

Osteoporosis. Clinical cases and literature review Catherine Bakewell, MD. Quick overview. Definition—(per WHO) normal bone density is a value within one standard deviation of the mean value in young adults of the same sex and race.

elina
Télécharger la présentation

Osteoporosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Osteoporosis Clinical cases and literature review Catherine Bakewell, MD

  2. Quick overview • Definition—(per WHO) normal bone density is a value within one standard deviation of the mean value in young adults of the same sex and race. • BMD btw 1 and 2.5 standard deviations below the mean is defined as osteopenia, • BMD > or = 2.5 standard deviations below the mean is defined as osteoporosis (and is associated with skeletal fragility)

  3. Risk Factors • History of fragility fracture in a first-degree relative • Low body weight (less than 58 kg [127 lb]) • Current cigarette smoking • Female sex • Estrogen deficiency at an early age (menopause before age 45 years or bilateral ovariectomy, prolonged premenopausal amenorrhea [greater than one year]) • White race • Advanced age • Lifelong low calcium intake • Alcoholism • Inadequate physical activity • Recurrent falls • Dementia • Impaired eyesight despite adequate correction • Poor health/frailty • Medical conditions: chronic obstructive pulmonary disease, gastrectomy, hyperparathyroidism, hypogonadism, multiple myeloma, celiac disease • Glucocorticoid therapy for more than three months • Other drugs: anticonvulsants, GnRH agonists, lithium, excessivedoses of thyroid hormone

  4. Screening • BMD should be measured in all postmenopausal women < 65 y.o. who have one or more risk factors for osteoporosis. • Measurement of BMD is also recommended for all women 65 years and older.

  5. Mrs. T • A 53 year old woman presents to your clinic with concerns about osteoporosis, and she is requesting screening. • What do you want to know?

  6. Mrs T. (cont) • You decide to get a DXA scan, which shows: • A total T score of –2.0 at the hip, and –1.7 at the spine. • She complains of some height loss, but a chest X-ray is negative for compression fractures.

  7. Treatment of Osteopenia • You tell her she should take calcium and vitamin D supplementation. • She asks “didn’t they just do a study that showed that that didn’t work? I thought I read something about that in the paper.”

  8. EBM • Jackson et al, N Engl J Med. 2006. “Calcium plus Vitamin D supplementation and the risk of fractures.” • Design: Randomized, placebo-controlled trial, 36K women at 40 different sites, healthy, postmenopausal aged 50 – 70 years (of note, corticosteriod use was an exclusion criteria). Mean follow up period: 7 years. • Intervention: CaCO3 1000mg plus Vitamin D 400 IU daily. Personal use of calcium, vitamin D, bisphosphonates, and calcitonin was allowed. 52% of women were taking HT at baseline. • Outcomes: no difference in number of hip, wrist, vertebral, or total fractures. At year 6, Calcium plus vitamin D did increase BMD by 0.9% at the hip but not at the spine. • Conclusions: No significant benefit, slight increase in risk of kidney stones

  9. Problems? Flaws?

  10. Study limitations • Although not statistically significant, treated women did have 12% fewer hip fractures, the type of fracture associated with the largest morbidity and mortality. Plus bone density at the hip increased slightly. • Women in this trial were also at low risk; many had already had the benefits of taking large amounts of calcium and vitamin D, and more than half were taking hormone therapy. • Vitamin D dosing was potentially inadequate (further discussion to follow) • 40% of women in the intervention group did not take the supplements

  11. What doses do you recommend?

  12. Vitamin D • Bishoff-Ferrari et al. performed meta-analysis (JAMA 2005) • 12 studies included: examined efficacy of different doses of Vitamin D • Conlusion: oral Vit D btw 700-800 IU/d reduces risk of non-vertebral fractures; 400 IU/d is not sufficient.

  13. Calcium • To maintain neutral calcium balance: • 1,000mg/d for premenopausal women • 1,500 mg/d for postmenopausal women

  14. Counselling • Mrs. T needs to be counselled re:

  15. Bisphosphonates for Osteopenia • Should Mrs. T be started on Fosamax?

  16. Physiologic effects • * Decreased bone resorption * Decreased bone formation by 70-95% * Increased mineralization density * Slight increase in bone volume * Increase bone strength first 5 years * Decreased fracture rate first 5 years,compared to placebo * Half-life in bone greater than 10 years * Long-term effects on bone unknown

  17. Guidelines • National Osteoporosis Foundation recommends tx for women with T < -2.0 or < -1.5 with risk factors.

  18. Schousboe et al, 2005 • Modeled cost-effectiveness of treating osteopenic women with alendronate for 5 years. • Compared cost per quality-adjusted life-year (QALY) of tx vs not tx women aged 55 - 75, femoral neck scores of – 1.5 to – 2.4. • Costs ranged from 74 K to 322K per QALY gained.

  19. Conclusions • Therapy only deemed cost effective in women who had risk factors unrelated to BMD, such as dementia, visual impairment, or frequent falls. • Current recommendation is to reserve bisphosphonates for women with T scores of –2.5, or those with osteopenia and pathologic fracture.

  20. Mrs T. Goes Home • So you decide that Mrs. T should start with supplementation and lifestyle modification, and undergo repeat DEXA scan in 2 years time.

  21. What about other therapies? • Calcitonin • SERMs • Estrogen • Intermittant PTH

  22. Calcitonin • produced by cells in the thyroid gland • acts directly on osteoclasts to stop bone resorption • Taken as a nasal spray (Miacalcin), dose 200 units per spray (per day) • More expensive than bisphosphonate • Very safe, moderately effective

  23. Estrogen • Reasonable to start under age 60 (or for first ten post-menopausal years). • Most physicians only recommend for treatment of post menopausal symptoms. • Excellent at maintaining bone mineral density. • Consider switching to SERM after 5 – 10 years.

  24. Selective Estrogen Receptor Modulators (ex:Raloxifene) • Prevents vertebral osteoporotic fractures in women with osteoporosis, and stabilizes bone density. • Physiological substitute for estrogen at the bone. • Increased risk of thrombosis. • Can worsen menopausal symptoms.

  25. Ms. B • Ms B is a 67 yr old woman with a T-score of –3. You have had her on Ca, Vit D, and Boniva(due to her awful GERD) for 2 years now. She develops the acute onset of thoracic back pain, and CXR reveals a new compression fracture. • What are you going to do?!

  26. Intermittent PTH • Recombinant (1-34) variant FDA approved in 2002, stimulates both osteoclasts and osteoblasts. • Intermittent spikes of PTH stimulate more bone formation than resorption. • Administered at a dose of 20 mcg/day SC for 18 to 24 months. • After discontinuation,patients should be treated for the next two years with an anti-resorping medication; otherwise the bone density will decrease. • Other doses, durations are being experimented with, but not officially approved.

  27. Mrs. S • Mrs. S is a 78 year old woman with osteoporosis (T score –2.6 at the hip by DEXA 2 years ago) on Fosamax 70 mg weekly. • She is concerned because she has heard about reports of dead jaw bone in people on this medication. • What do you say to her?

  28. Woo et al, Annals, 2006 • Systematic review– Bisphosphonates and Osteonecrosis of the Jaws • 368 patient cases • Strongly assoc with use of aminobisphosphonates (IV preparation), for people with malignancy, related to severe suppression of bone turnover • 94% of pts tx with pamidronate or zoledronic acid or both

  29. Osteonecrosis, cont • 85% of affected patients have metatstatic breast cancer or multiple myeloma. Only 4% have osteoporosis. • For pts with cancer receiving IV bisphosphonate, prevalence 6 – 10%. • In pts on alendronate for osteoporosis, prevalence unknown. • 60% of all cases occur after dental surgery (such as tooth extraction), the remaining 40% are assoc with denture or physical trauma.

  30. Osteonecrosis, cont

  31. Osteonecrosis, cont

  32. Osteonecrosis, cont

  33. Mrs S. • You can reassure Mrs. S that her chances of osteonecrosis are very, very low. • However, (for other patients) it is reasonable to hold off on initation of bisphosphonate until after necessary dental procedures.

  34. Ms. W • Ms W is a charming 45 year old woman with rheumatoid arthritis, who has been on low dose prednisone (5mg/day) for 10 years now. • What is her risk of osteoporosis?

  35. Glucocorticoid induced bone loss • Unlike other agents that increase bone loss (thyroxine, sustained PTH), glucocorticoids accelerate resorption while inhibiting bone formation. • Patients beginning on high dose prednisone (mean 21mg/day) lost a mean of 27% of their L-spine in one year (Reid et al, 1990). • Luckily, the decline in BMD slows thereafter.

  36. Mechanisms for glucocorticoid induced osteoporosis

  37. General guidelines • Keep duration of therapy as short as possible • Consider high dose pulse therapy rather than tx for weeks or months • Don’t forget the basics (weight bearing exercise, smoking cessation, minimize alcohol)

  38. Screening • Measure baseline BMD if it is anticipated that a patient will be on glucocorticoids for > 3 mo. • DEXA repeated yearly if on preventative therapy.

  39. Supplementation • Adequate Calcium and vitamin D supplementation appear to largely negate the effects of low dose (up to 10mg/day) steroid administration. (Buckley et al, 1996; Saag et al, 1998). • Recommended supplemenation doses that for postmenopausal women: 1500mg Calcium plus 800IU of Vitamin D.

  40. HRT • For premenopausal women with oligo or amenorrhea on steroids, the ACR recommends addition of oral contraceptive. • For men with testosterone deficiency (decreased libido, fatigue) consider testosterone supplementation.

  41. Bisphosphonates • Should be initiated on essentially everyone initiating long-term glucocorticoid therapy (>5mg/day for >3 months) except those on HRT (unless pt has fxr on HRT) or premenopausal women who may become pregnant. • ACR Recommendations (2001 Update)

  42. What would Schousboe say? • Given the high costs of bisphosphonate for prevention, perhaps a better strategy would be: • DEXA at baseline and yearly • Start bisphosphonate tx only if BMD is abnormal (T score < -1.0). • Alendronate 35mg weekly for prevention, and 70mg weekly for treatment.

  43. Calcitonin • Consider calcitonin if bisphosphonate contraindicated or not tolerated. • May also reduce pain from prior fractures.

  44. Thiazides • Measure urinary calcium excretion. • Thiazide diuretics (and salt restriction) shown to decrease calcium excretion. • Enthusiasm tempered by lack of evidence that thiazides increase BMD in pts on corticosteriods.

  45. Ms W. • Should have a DEXA scan at the hip and lumbar spine. • Should be on Calcium and Vit D. • Add bisphosphonate if T score < -1.0. • Consider addition of thiazide, especially if hypertensive or she has elevated urinary calcium excretion. • Evaluate for estrogen deficiency.

  46. References • Bischoff-Ferrari HA, Wellet WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randonized controlled trials. JAMA 2005; 293:2257-64. • Buckley LM, Leib ES, Cartularo KS, et al. Calcium and Vitamin D3 supplementation prevents loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med. 1996; 125: 961. • Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669-83. • Laan, RF, Van Riel, PL, Van de Putte, LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993; 119:963 • Ott S. Osteoporosis and bone physiology: description, diagnosis, treatment, and explanation of underlying physiology. Retrieved on September 26th, 2006 from University of Washington Web Site: http://courses.washington.edu/bonephys/ • Primer on the Rheumatic Diseases. 12th Ed. Atlanta, GA: Arthritis Foundation; 2001: 511-27; 596. • Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001; 44:1496. • Reid, IR, Heap, SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990; 150:2545. • Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998; 339: 292. • Schousboe JT, Nyman JA, Kane RL, et al. Cost-effectiveness of aldenronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142: 734 – 41. • Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and Osteonecrosis of the Jaws. Ann Intern Med. 2006;144:753-761.

More Related